Q2 2020 13F Holders as of 6/30/2020
-
Type / Class
-
Equity / Common Stock, $0.0001 Par Value Per Share
-
Shares outstanding
-
108M
-
Number of holders
-
145
-
Total 13F shares, excl. options
-
48.8M
-
Shares change
-
+1.3M
-
Total reported value, excl. options
-
$1.25B
-
Value change
-
+$59.1M
-
Put/Call ratio
-
0.38
-
Number of buys
-
88
-
Number of sells
-
-51
-
Price
-
$25.67
Significant Holders of Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share (ITCI) as of Q2 2020
195 filings reported holding ITCI - Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share as of Q2 2020.
Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share (ITCI) has 145 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 48.8M shares
of 108M outstanding shares and own 45.23% of the company stock.
Largest 10 shareholders include FMR LLC (8.53M shares), VANGUARD GROUP INC (5.27M shares), BlackRock Inc. (5.01M shares), Bellevue Group AG (3.78M shares), WASATCH ADVISORS INC (3.66M shares), DIMENSIONAL FUND ADVISORS LP (1.6M shares), STATE STREET CORP (1.36M shares), MARSHALL WACE, LLP (1.32M shares), SAMLYN CAPITAL, LLC (1.18M shares), and SCHRODER INVESTMENT MANAGEMENT GROUP (1.12M shares).
This table shows the top 145 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.